See Why RenovoRx Stock Is Shooting Higher On Tuesday
The FDA has granted a new 510(k) clearance to RenovoRx Inc’s (NASDAQ:RNXT) RenovoCath Delivery System. The RenovoCath Delivery System is the device component…
RenovoRx Receives New 510(k) Clearance For Its RenovoCath Delivery System Designed For Targeted Treatment Of Solid Tumors
RenovoRx, Inc. (NASDAQ:RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its
54 Biggest Movers From Yesterday
Gainers
Focus Universal Inc. (NASDAQ: FCUV) shares climbed 278% to close at $19.28 on Wednesday. The stock started trading on Nasdaq Capital Market yesterday.
38 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Focus Universal Inc. (NASDAQ: FCUV) shares jumped 108.2% to $10.62. The stock started trading on Nasdaq Capital Market yesterday.
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
18 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Regional Health Properties Inc (NYSE: RHE) rose 50.3% to $12.49 in pre-market trading after jumping over 15% on Monday. The company, earlier during the month, reported Q2 results.
48 Biggest Movers From Yesterday
Gainers
RenovoRx, Inc. (NASDAQ: RNXT) climbed 107.8% to close at $16.02 on Monday after the company was granted FDA clearance for ‘Catheter, Intravascular Occluding, Temporary.’ The company recently priced its IPO at $9 per unit.
RenovoRx Shares See Volume; Co Granted FDA Clearance For ‘Catheter, Intravascular Occluding, Temporary’
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K212324
60 Biggest Movers From Friday
Gainers
Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share.